Insmed doses first patient in European study of Arikace
CLEAR-108 is a 300-patient randomized phase 3 trial comparing Arikace 560mg, delivered once daily via PARI Pharma’s eFlow nebulizer system to Tobi (inhaled tobramycin solution). The eFlow nebulizer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.